Prostate cancer kills about thirty thousand people a year. In most men, prostate cancer isn’t likely to kill them before something else does. But since prostate cancer still kills so many men,
Nearly 100% of men who have local or regional prostate cancer will last more than five years after diagnosis. Some men (about seven %) have more advanced prostate cancer at the time of diagnosis. Once prostate cancer has spread exceeding the prostate, survival chances fall.
Scientists develop an experimental test in which, through urine, prostate cancer and its level of aggressiveness could be detected.
This sample would avoid biopsies in patients and could find the disease much earlier.
Researchers from the University of East Anglia and the University Hospital of Norfolk and Norwich named this verification as Prostate Urine Risk (PUR), which can also be predicted up to five years earlier than with existing clinical methods if Patients require treatment.
This scientific advance research would avoid an initial biopsy and subsequent invasive treatments in low-risk patients in a large number of men; Also, it could differentiate between patients without prostate cancer, low risk and those who need treatment.
Shea Connell, a lead author of the study, said:
Prostate cancer is more commonly a disease in which men die and not because of it. Unfortunately, we cannot currently determine which men diagnosed with cancer need radical treatment and which do not.
With the PUR, the genes in the urine of 537 men were analyzed, using four signatures to evaluate both non-cancerous tissues and risk groups and thus determine how aggressive the cancer is. The test identified men who were up to eight times less likely to need treatment within five years after diagnosis.
The Movember Foundation, the sponsor of the research program through which the PUR emerged, considered that this discovery “has enormous potential to transform the diagnosis and treatment of prostate cancer.”